Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Biologic skin substitute products include tissue-engineered products, which are designed to either temporarily or permanently replace the altered skin. Skin substitutes are commonly used products for wound management and have application for treating various ailments such as pressure ulcers, diabetic neuropathic ulcers, and vascular insufficiency ulcers.

Market Dynamics

Increasing incidences of chronic ulcers, owing to rising prevalence of diabetes, increasing surgical procedures, and rise in trauma cases are major driving factors for growth of wound care biologics market. According to the survey by World Health Organization, 2014, injuries resulting from traffic collisions, drowning, poisoning, falls or burns account for 9% of the global mortality. Also, according to a study by BMJ Journal Injury Prevention, 2013, an estimated 973 million people sustained injuries that warranted some type of healthcare and 4.8 million people died from injuries. The Journal also stated that major injury causes included road injury (29.1%), self-harm (17.6%), falls (11.6%), and interpersonal violence (8.5%). Manufacturers are also focused on extensive research and development to develop new products and expand their product portfolio. For instance, in 2016, Integra LifeSciences Holdings Corporation received FDA approval for Integra Dermal Regeneration Template (IDRT) for the treatment of diabetic foot ulcers that is marketed under the name of Integra Omnigraft Dermal Regeneration Matrix. Moreover, public awareness for biologics has positively contributed to the market growth, as people are opting for enhanced medical care for preventing wounds to minimize the morbidity associated with the formation of chronic wounds. However, higher cost of the biologics and stringent regulatory approvals for launch of innovative tissue engineered products are hindering growth of the wound care biologics market.

Key features of the study

• This report provides in-depth analysis of wound care biologics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global wound care biologics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global wound care biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the wound care biologics market

Market Segmentation

• By Product Type (Revenue, USD Bn, 2021-2033)
  • Skin Substitute
    • Biological
    • Allografts
    • Xenografts
    • Others
  • Synthetic
    • Topical Agents
• By Wound Type (Revenue, USD Bn, 2021-2033)
  • Chronic Wounds
    • Diabetic Foot Ulcers (DFU)
    • Venous Leg Ulcers
    • Others
  • Acute Wounds
    • Burns
    • Surgical & Traumatic Wounds
    • Others
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Competitive Landscape
  • Smith & Nephew Plc.
  • Organogenesis, Inc.
  • Integra Lifesciences Holdings Corporation
  • Skye Biologics
  • Alphatec Holdings, Inc.
  • Solsys Medical LLC
  • Amino Technology LLC
  • Osiris Therapeutics, Inc.